[Comparative clinical study of SF-SP therapy and SF-SP plus BH-AC therapy in gastrointestinal cancer. Tokyo Cancer Chemotherapy Cooperative Study Group].
SF-SP which contains sustained release granules of tegafur has been reported to be effective for gastrointestinal and breast cancer. HB-AC, which is an anti-leukemic agent, is known to have considerable activity against a variety of transplanted solid tumors in rats and mice. A comparative clinical study was therefore conducted by randomized controlled trial on the two different chemotherapies, involving as SF-SP group and as SF-SP plus BH-AC group. Among 58 patients, 42 were evaluable for response (SF-SP: 20/30, SF-SP plus BH-AC: 22/28). The partial response rate of SF-SP was 15.0% (3/20) and that of SF-SP plus BH-AC was 13.6% (3/22). The toxicity rates of SF-SP and SF-SP plus BH-AC were 33.3% (10/30) and 36.0% (9/25), respectively. These results indicated that the two therapies were similar in both response and toxicity rates. However, the response appeared faster in the case of SF-SP plus BH-AC therapy than in that of SF-SP therapy.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D013160:Splenic Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D003561:Cytarabine; D005641:Tegafur; C015019:enocitabine